Splice mutation 1811+1.6kbA>G causes severe cystic fibrosis with pancreatic insufficiency: report of 11 compound heterozygous and two homozygous patients

M P Reboul, E Bieth, M Fayon, N Biteau, R Barbier, C Dromer, M Desgeorges, M Claustres, F Bremont, D Lacombe, A Iron

Cystic fibrosis (CF, OMIM 219700) is one of the most common severe hereditary diseases occurring in white populations. It is characterised by considerable heterogeneity in the mutational spectrum and a diverse phenotypic presentation, which justifies extensive studies on the correlation between the cystic fibrosis transmembrane regulator (CFTR) genotype and the CF phenotype. Genotype-phenotype data are available especially for common genotypes, but information remains scarce or lacking for genotypes of compound heterozygotes with a rare mutation and homozygotes for a rare mutation. Among rare CFTR gene mutations, 1811+1.6kbA>G is practically absent in CF patients from other parts of France, but it is not rare in patients genotyped in the south west of France, occurring in fourth place after F508del, G542X, and N1303K. Its frequency is 3.4% and higher than 5% with reference to the number of CF chromosomes with a south western geographical origin. The mutation 1811+1.6kbA>G, located in intron 11 of the CFTR gene, is (with the mutation 3849+10kbC>T) one of the only two splicing mutations of the CFTR gene that generates a new exon (1811+1.6kbA>G creates a donor site, 3849+10kbC>T an acceptor site). Furthermore, it was previously ranked by Chillon et al among class I mutations responsible for defective CFTR protein production and a severe CF phenotype. However, because it allows a reduced synthesis of normal protein, the mutation 1811+1.6kbA>G has also been reported in class V. According to the recent classification proposed by Welsh et al, the mutation 1811+1.6kbA>G now belongs definitely to the “new” class I. The present report aims to study as well as possible the clinical severity of the mutation 1811+1.6kbA>G. The clinical data from 13 CF patients originating from the south west region of France and bearing 1811+1.6kbA>G (11 compound heterozygotes and two homozygotes) were collected.

Patients and methods

The clinical characteristics of 13 patients carrying the mutation 1811+1.6kbA>G (Table 1) were obtained from various hospitals in the Aquitaine and Midi-Pyrénées regions of France. The parameters recorded were: (1) for all patients, the current age, age of diagnosis, clinical diagnosis, time of follow up, sweat chloride concentration, colonisation by Pseudomonas aeruginosa (three consecutive positive cultures), height and weight, pancreatic exocrine function (mainly assessed clinically and sometimes with the faecal elastase value); (2) only for patients older than 5, the maximal expired volume per second (FEV1) and the forced vital capacity (FVC); (3) for the majority of patients, the Brasfield radiological score and the Shiwachman score.

Genotyping of CFTR gene mutations was carried out on DNA extracted from leucocytes in a two step procedure. First, the most common mutations in the French population were investigated by multiplex PCR amplification and subsequent reverse dot blot hybridisation by using INNO-LIPA CF2, then INNO-LIPA CFTR12 and CFTR17+Tn assays (Innogenetics, Zwijnaarde, Belgium). When one or two mutations were still to be found, an exhaustive search for uncommon mutations was done by denaturing gradient gel electrophoresis (DGGE) and automatic sequencing with Dye Terminators on ABI PRISM 377 (Applied Biosystems). For the first patients investigated, the mutation 1811+1.6kbA>G was detected by automatic sequencing (ABI PRISM 377, Applied Biosystems) of a specific region of intron 11 according to a procedure used in our laboratory (unpublished data). Then the search for the mutation 1811+1.6kbA>G was done directly by PCR of intron 11 and FokI digestion simultaneously with the reverse dot blot step.

Results

The results of genotyping the 13 CF patients carrying the mutation 1811+1.6kbA>G were: two homozygotes for 1811+1.6kbA>G/1811+1.6kbA>G and 11 compound heterozygotes for 1811+1.6kbA>G and for another CFTR mutation, that is, F508del (n=6), N1303K (n=2), G542X (n=1), 2183 AA>G (n=1), and W1063X (n=1). No complex alleles were found among the 13 patients with 1811+1.6kbA>G.

Table 1 lists the clinical characteristics of all the patients with the mutation 1811+1.6kbA>G. They are very similar to patients homozygous for F508del or compound heterozygotes for two severe CFTR mutations. All presented a typical form of cystic fibrosis that was diagnosed early (nine out of 13 before the age of 1 year), then confirmed by a positive sweat test; for the 13 patients, the chloride mean (SD) and the median (min-max) values are respectively 88 (SD 22) and 82 (57-120) mmol/l. Three patients (23%) had neonatal meconium ileus. In 10 cases, there was colonisation by Pseudomonas aeruginosa and in 11 patients growth delay was observed. The obstructive syndrome of the lungs was severe and always accompanied by pancreatic insufficiency (PI).
Table 1

Characteristics of the 13 CF patients with mutation 1811+1.6kbA>G

<table>
<thead>
<tr>
<th>Patient No</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
<th>13</th>
</tr>
</thead>
<tbody>
<tr>
<td>CF family history</td>
<td>Digestive</td>
<td>Meconium ileus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>genetic defect</td>
<td></td>
<td>1811</td>
<td></td>
<td>2183</td>
<td>AA</td>
<td>G</td>
<td>F508del</td>
<td>F508del</td>
<td>F508del</td>
<td>F508del</td>
<td>F508del</td>
<td>G542X</td>
<td>N1303K</td>
</tr>
<tr>
<td>Sweat chloride (mmol/l)</td>
<td>120</td>
<td>70</td>
<td>77</td>
<td>90</td>
<td>82</td>
<td>115</td>
<td>70</td>
<td>120</td>
<td>57</td>
<td>77</td>
<td>63</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Sex</td>
<td>M</td>
<td>MF</td>
<td>F</td>
<td>F</td>
<td>M</td>
<td>F</td>
<td>MF</td>
<td>MF</td>
<td>FM</td>
<td>M</td>
<td>F</td>
<td>F</td>
<td>MF</td>
</tr>
<tr>
<td>Current age (y)</td>
<td>8.3</td>
<td>4.9</td>
<td>12.5</td>
<td>2.2</td>
<td>24.2</td>
<td>22.1</td>
<td>10.6</td>
<td>10.6</td>
<td>4.5</td>
<td>3.5</td>
<td>3.5</td>
<td>3.5</td>
<td>3.5</td>
</tr>
<tr>
<td>Age at diagnosis (y)</td>
<td>0.3</td>
<td>0</td>
<td>0.1</td>
<td>0</td>
<td>0.5</td>
<td>1</td>
<td>10</td>
<td>4</td>
<td>0</td>
<td>3</td>
<td>0.1</td>
<td>6</td>
<td>0.3</td>
</tr>
<tr>
<td>Pulmonary hypertrophy</td>
<td>Digestive, hypotrophy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dehydration</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight (SD)</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>8</td>
<td>9</td>
<td>10</td>
<td>11</td>
<td>12</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Height (SD)</td>
<td>20</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>8</td>
<td>9</td>
<td>10</td>
<td>11</td>
<td>12</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>FEV1 (% predicted)</td>
<td>111</td>
<td>104</td>
<td>35</td>
<td>33</td>
<td>54</td>
<td>70</td>
<td>68</td>
<td>30</td>
<td>20</td>
<td>16</td>
<td>12</td>
<td>10</td>
<td>80</td>
</tr>
<tr>
<td>FVC1 (% predicted)</td>
<td>102</td>
<td>102</td>
<td>45</td>
<td>58</td>
<td>67</td>
<td>90</td>
<td>40</td>
<td>20</td>
<td>16</td>
<td>12</td>
<td>10</td>
<td>80</td>
<td>60</td>
</tr>
<tr>
<td>Brasfield score</td>
<td>9</td>
<td>13</td>
<td>5</td>
<td>2</td>
<td>18</td>
<td>20</td>
<td>16</td>
<td>0</td>
<td>10</td>
<td>12</td>
<td>21</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Malnutrition</td>
<td>Severe</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastro-oesophageal reflux</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreatic insufficiency</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>P. aeruginosa colonisation</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Shwachman score</td>
<td>90</td>
<td>80</td>
<td>50</td>
<td>55</td>
<td>60</td>
<td>95</td>
<td>80</td>
<td>55</td>
<td>35</td>
<td>30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elastase (µg/g)‡</td>
<td>20</td>
<td>16</td>
<td>15</td>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dehydration</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastro-oesophageal reflux</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreatic insufficiency</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Elastase (µg/g)‡</td>
<td>20</td>
<td>16</td>
<td>15</td>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

DISCUSSION

Up to 2000, we used to consider five classes of CFTR mutations defined according to the functionality of the CFTR protein. They correspond either to an absence of protein production (class I), or a trafficking defect (class II), or defective regulation (class III), or defective conductance (class IV), or a reduced level of normal messenger RNA or protein (class V). A new class of CFTR mutation (class VI) has recently been proposed leading to a decreased stability of the protein. However, recently, Welsh et al have slightly modified the classification of CFTR gene mutations. They defined a new class I corresponding to either defective (previous class I) or reduced (previous class V) protein production. Classes II, III, and IV remain the same. What was called class VI before may now be considered as the “new” class V.

The genotype-phenotype relationships of some CFTR mutations are easy to classify. This is the case for nonsense and frameshift mutations always associated with severe CF with PI; they come into class I (for instance, G542X) when they lead to an absence of functional CFTR and into the “new” class V (for instance, Q1412X) when they cause the presence of a functional but unstable CFTR at the apical membrane. A severe CF presentation correlates also with class II mutations such as the amino acid deletion F508del.

There is considerable heterogeneity in missense mutations. Some of them are always responsible for a unique phenotype that can be either CF-PI (for instance, the case of N1303K in class II, G531D in class III, and R1066C in class IV), or CF-PS (for instance, the case of G551S in class III) or CBVAD for D1152H (class IV). Other missense mutations show considerable phenotypic variation, such as CF-PI or CF-PS with R334W, CF-PS or congenital bilateral absence of the vas deferens (CVABD) with R117H (class IV). Splicing mutations also have a variable impact on the phenotype depending on the position of the nucleotide change at the splice site. When one of the two nucleotides beginning or ending introns is concerned (for instance with 621+1G>T or 1717-1G>A), the mutation is in class I and CF is severe with PI. When the mutation occurs further from the exon-intron junction, the phenotype is less severe; CF-PS in the case of 2789+5G>A (class IV) and either CF-PS or CBVAD when the 5T allele is present.

Particular emphasis should be given to alternative splice mutations in class I that create a new exon. They result in reduced expression of functional CFTR channels in the apical membrane. They allow the presence of a small quantity of normal residual CFTR on which depends the degree of severity. These mutations, 3849+10kbC>T (intron 19) and 1811+1.6kbA>G (intron 11), are only two of the 1000 mutations reported so far (The Cystic Fibrosis Genetic Analysis Consortium, CFGAC: http://genet.sickkids.on.ca). Phenotypic variability has been largely reported for 3849+10kbC>T, but very few patients with 1811+1.6kbA>G, only compound heterozygotes, have been reported so far. Our results concerning 13 patients with the mutation 1811+1.6kbA>G including two homozygotes are in good agreement with previous data and confirm that this CF mutation is a severe one; all 13 patients had respiratory and digestive disease as shown by their clinical characteristics and by comparison with CF patients homozygous for F508del. The severity of the disease is similar to the one resulting from F508del with even more severe growth retardation with 1811+1.6kbA>G. The clinical features of the homozygotes 1811+1.6kbA>G/1811+1.6kbA>G (patients 1 and 2 in table 1) show that the phenotype remains severe, whereas one might expect a moderation of the phenotype because of twice as much theoretical amount of functional CFTR than in patients with one dose of mutation 1811+1.6kbA>G.

In conclusion, we suggest that the CF-PI mutation 1811+1.6kbA>G ranks among the mutations of class I with
reduced protein production as an exception, since all the other class I mutations of this kind cause considerable phenotypic variability in CF disease and not limited to CF-PI. It is not known why the phenotype is not attenuated despite the presence of higher amounts of normal CFTR protein in patients homozygous for 1811+1.6kbA>G. Further investigations including in vitro expression of the mutation are needed for a better understanding of the mechanism of this CFTR mutation.

ACKNOWLEDGEMENTS

We thank the Observatoire National de la Mucoviscidose, the Institut National d’Etudes Démographiques, and the Association Vaincre La Mucoviscidose for their help in the collection of data.

Authors’ affiliations

M P Reboul, N Biteau, D Lacombe, A Iron, Service de Génétique Médicale, CHU Pellegrin, Bordeaux, France
E Bieth, Service de Génétique Médicale, CHU Purpan, Toulouse, France
M Foyon, Département de Pédiatrie, CHU Pellegrin, Bordeaux, France
R Barbier, Service de Pédiatrie, CH, Dax, France
C Dromer, Service de Chirurgie Thoracique, CHU Haut-Lévêque, Pessac, France
M Desgeorges, M Claustres, Laboratoire de Génétique Moléculaire, CHU, CNRS UPR 1142, Institut de Biologie, Montpellier, France
F Bremont, Département de Pédiatrie, CHU, Hôpital des Enfants, Toulouse, France

Correspondence to: Dr A Iron, Laboratoire de Génétique Moléculaire, Hôpital Pellegrin-Tripode, Place Amélie Raba-Léon, 33076 Bordeaux Cedex, France; albert.iron@chu-bordeaux.fr

REFERENCES


Splice mutation 1811+1.6kbA>G causes severe cystic fibrosis with pancreatic insufficiency: report of 11 compound heterozygous and two homozygous patients

M P Reboul, E Bieth, M Fayon, N Biteau, R Barbier, C Dromer, M Desgeorges, M Claustres, F Bremont, D Lacombe and A Iron

J Med Genet 2002 39: e73
doi: 10.1136/jmg.39.11.e73

Updated information and services can be found at: http://jmg.bmj.com/content/39/11/e73

These include:

References
This article cites 15 articles, 2 of which you can access for free at: http://jmg.bmj.com/content/39/11/e73#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Cystic fibrosis (39)
- Molecular genetics (1254)
- Pancreas and biliary tract (110)
- Genetic screening / counselling (886)
- Clinical diagnostic tests (356)
- Immunology (including allergy) (604)
- JMG Online mutation reports (168)

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/